For the purpose of evaluating objectively the effectiveness, safety and usefulness of Lenampicillin (LAPC, 250 mg, q. i. d.) for acute suppurative otitis media and acute exacerbation of chronic suppurative otitis media, a double blind controlled study has been carried out by using Talampicillin (TAPC, 250 mg, q. i. d.) as a control drug. L Although LAPC group showed a higher rate in the clinical effect for acute suppurative otitis media by the doctor in charge with such effectiveness as LAPC group 84.2 % (32/38) and TAPC group 76.2 % (32/42), significant difference was not found. The effectiveness for acute exacerbation of chronic suppurative otitis media showed no significant difference likewise with LAPC group 54.5 % (36/66) and TAPC group 53.2 % (33/62). According to the judgement based on the criteria by the Committee, the LAPC group showed a superior tendency (p<0.1) in the effectiveness of acute suppurative otitis media with 89.5 % (34/38) as against TAPC group 73.8 96 (31/42). The effectiveness for acute exacerbation of chronic suppurative otitis media, however, showed no significant difference between them, with LAPC group 57.6 % (38/66) and TAPC group 53.2 % (33/62). 2. In the bacteriological of-fect, no significant difference was recognized with such eradication rate as LAPC group 68.8 % and TAPC group 65.3 %. 3. In regard to the safety, no significant difference in the appearance of side effects was recognized between both drugs, with LAPC group 7.9 96 (10/127) and TAPC group 4.6 % (6/130). 4. As for the usefulness, in terms of the rate of usefulness consisting of “quite satisfied” and “satisfied”, no significant difference was recognized with LAPC group 65.7 % (71/108) and TAPC group 61.3 96 (65/106). From the results thus obtained above, the LAPC can be considered as highly useful drug being capable of expecting the same and/or higher result when compared with TAPC for the treatment of suppurative otitis media.
抄録全体を表示